Analyst Phil Nadeau of TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $120.00.
Phil Nadeau has given his Buy rating due to a combination of factors that highlight BioMarin Pharmaceutical’s strong financial performance and promising growth prospects. The company’s fourth-quarter revenue and earnings per share significantly exceeded expectations, driven by robust demand for Voxzogo and the core enzyme franchise. The positive momentum is expected to continue, as BioMarin’s 2025 guidance projects healthy revenue and earnings growth, supported by improved operating margins and disciplined cost management.
Additionally, Voxzogo’s international market expansion and substantial contribution to overall revenue growth underscore its role as a key driver for BioMarin’s future success. With a strategic plan to increase its presence in new countries and the anticipated progress of its pipeline milestones in 2025, BioMarin is well-positioned to maintain its competitive edge and deliver strong shareholder value, justifying Phil Nadeau’s Buy rating.
In another report released on February 4, Morgan Stanley also maintained a Buy rating on the stock with a $105.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com